Operationalizing Subcutaneous Immune Checkpoint Inhibitors in Clinical Practice

Operationalizing Subcutaneous Immune Checkpoint Inhibitors in Clinical Practice

Panelists discuss how implementing subcutaneous checkpoint inhibitors requires navigating temporary J-codes and reimbursement delays, considering economic impacts on institutional revenue streams, building indication-specific electronic treatment plans, and adopting provider-driven rather than mandated prescribing approaches while anticipating future dynamics including biosimilar competition and Inflation Reduction Act implications.

Operationalizing SubQ Immune Checkpoint Inhibitors in Clinical Practice

Panelists discuss how operationalizing subcutaneous checkpoint inhibitors requires navigating temporary J-codes and reimbursement delays, maintaining physician-driven prescribing rather than automatic substitutions, considering future dynamics around 2028 biosimilar availability and Inflation Reduction Act impacts, and balancing patient convenience against potential economic implications from shifting away from intravenous (IV) formulations.